Lv3
280 积分 2024-10-16 加入
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
6小时前
已完结
Detection of SEZ6, a therapeutic target, in medullary thyroid carcinoma
11个月前
已完结
The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development
11个月前
已完结
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors
1年前
已完结
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial
1年前
已完结
Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas
1年前
已完结
Preclinical Characterization of Catabolic Pathways and Metabolism of ABBV-011, a Novel Calicheamicin-Based SEZ6-Targeting Antibody-Drug Conjugate
1年前
已完结
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study
1年前
已完结
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study
1年前
已完结
皖公网安备34019202002308
